26 July 2016

Acino divests its patch business to Luye Pharma Group Ltd.



Luye Pharma Group Ltd. has entered into an agreement to acquire the TDS business from Acino, through the purchase of the entire issued share capital of Acino AG and Acino Supply AG for EUR 245,000,000. The target group is a Europe based global leader in advanced transdermal drug delivery systems (TDS) and is one of the largest independent TDS manufacturers in Europe. Closing is expected to occur in the second half of 2016.

Walder Wyss comprehensively advised Luye Pharma regarding the Swiss law aspects of this transaction. The team was led by Alexander Gutmans (Partner, Corporate/M&A) and Robert von Rosen (Managing Associate, Corporate) and also included Dirk Spacek (Associate, IP/IT) and Jessica Aeschbach Flórez (Associate, Corporate).

News

News

26 July 2016

Acino divests its patch business to Luye Pharma Group Ltd.

Luye Pharma Group Ltd. has entered into an agreement to acquire the TDS business from Acino, through the purchase of the entire issued share capital of Acino AG and Acino Supply AG for EUR 245,000,000. The target group is a Europe based global leader in advanced transdermal drug delivery systems (TDS) and is one of the largest independent TDS manufacturers in Europe. Closing is expected to occur in the second half of 2016.

Walder Wyss comprehensively advised Luye Pharma regarding the Swiss law aspects of this transaction. The team was led by Alexander Gutmans (Partner, Corporate/M&A) and Robert von Rosen (Managing Associate, Corporate) and also included Dirk Spacek (Associate, IP/IT) and Jessica Aeschbach Flórez (Associate, Corporate).